



*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.


1. (Original) A therapeutic agent for schizophrenia, which comprises, as an active ingredient, a compound of the formula (I)




wherein  $\text{R}^1$  is a  $\text{C}_2\text{-}\text{C}_6$  alkyl group or the formula (II)




wherein  $\text{R}^2$  is a hydrogen atom or an acetyl group and  $\text{R}^3$  is a  $\text{C}_1\text{-}\text{C}_6$  alkyl group, a cycloalkyl group or





wherein  $\text{R}^4$  and  $\text{R}^5$  are each independently a hydrogen atom or a  $\text{C}_1\text{-}\text{C}_6$  alkyl group, and in




of the formula (II),  $\text{R}^2$  and  $\text{R}^3$  may be linked to each other to form




wherein R<sup>6</sup> is a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub> alkyl group;




wherein R<sup>7</sup> and R<sup>8</sup> are each independently a hydrogen atom or a C<sub>1</sub>-C<sub>4</sub> alkyl group,



wherein R<sup>9</sup> and R<sup>10</sup> are each independently a hydrogen atom or a C<sub>1</sub>-C<sub>4</sub> alkyl group,



wherein R<sup>11</sup> is a hydrogen atom or a C<sub>1</sub>-C<sub>4</sub> alkyl group; and




wherein R<sup>12</sup> and R<sup>13</sup> are each independently a C<sub>1</sub>-C<sub>4</sub> alkyl group or may be linked to each other to form




wherein n is an integer of 2 to 6, or



wherein m is an integer of 2 or 3,




wherein  $\text{R}^{14}$  is a hydrogen atom or a C<sub>1</sub>-C<sub>4</sub> alkyl group,



wherein  $\text{R}^{15}$  is a hydrogen atom or an aralkyl group, or




provided that when




and  $\text{R}^7$  should not be a hydrogen atom, an enantiomer thereof, an acid addition salt thereof, or a hydrate or solvate thereof.


2. (Currently Amended) The therapeutic agent of claim 1, wherein the compound of the formula (I) is a compound of the formula (Ia)




wherein  $R^{1'}$  is a  $C_2-C_6$  alkyl group or the formula (II)'




wherein  $R^2$  is a hydrogen atom or an acetyl group, and  $R^3'$  is a  $C_1-C_6$  alkyl group or



wherein  $R^4$  and  $R^5$  are each independently a hydrogen atom or a  $C_1-C_6$  alkyl group, and in





of the formula (II)',  $R^2$  and  $R^3'$  may be linked to each other to form



wherein  $R^6$  is a hydrogen atom or a  $C_1-C_6$  alkyl group;


$R^9'$  and  $R^{10'}$  are each independently a  $C_1-C_4$  alkyl group; and




wherein  $R^{15'}$  is an aralkyl group, or



3. (Original) The therapeutic agent of claim 1, wherein the compound of the formula (I) is a 4-acylamino-5,6,7,8-tetrahydrofuro[2,3-b]quinoline derivative of the formula (Ib)



wherein  $R^{17}$  is a C<sub>2</sub>-C<sub>6</sub> alkyl group,



wherein  $R^6$  is a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub> alkyl group; and  
 $R^9$  and  $R^{10}$  are each independently a hydrogen atom or a C<sub>1</sub>-C<sub>4</sub> alkyl group.

4. (Original) The therapeutic agent of claim 1, wherein the compound of the formula (I) is 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetamide.

5. (Previously Presented) The therapeutic agent of claim 1, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

6. (Previously Presented) The therapeutic agent of claim 2, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

7. (Previously Presented) The therapeutic agent of claim 3, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

8. (Previously Presented) The therapeutic agent of claim 4, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.